Holen Sie sich die Stockscreener-App
1.095
2.03%
0.025
Schlusskurs vom Vortag:
$1.07
Offen:
$1.08
24-Stunden-Volumen:
285.94K
Relative Volume:
0.38
Marktkapitalisierung:
$95.03M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-93.61M
KGV:
-0.3192
EPS:
-3.43
Netto-Cashflow:
$-71.16M
1W Leistung:
+0.16%
1M Leistung:
-29.57%
6M Leistung:
-14.04%
1J Leistung:
+2.51%
1-Tages-Spanne:
$1.05
$1.10
1-Wochen-Bereich:
$1.02
$1.13
52-Wochen-Spanne:
$0.97
$2.11
Immunic Inc Stock (IMUX) Company Profile
Firmenname
Immunic Inc
Sektor
Branche
Telefon
(332) 255-9818
Adresse
1200 AVENUE OF THE AMERICAS, NEW YORK
Vergleichen Sie IMUX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| IMUX | 1.09 | 95.03M | 0 | -93.61M | -71.16M | -3.43 |
| VRTX | 450.61 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 749.05 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.59 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.41 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.82 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-04-15 | Eingeleitet | Aegis Capital | Buy |
| 2021-03-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-07 | Fortgesetzt | ROTH Capital | Buy |
| 2020-07-20 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-06-05 | Eingeleitet | Wedbush | Outperform |
| 2020-05-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-07-11 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Immunic Inc Aktie (IMUX) Neueste Nachrichten
Immunic's IMU-856 shows potential in gastrointestinal health trialsICYMI - Proactive Investors UK
Immunic, Inc. (NASDAQ:IMUX) Short Interest Update - MarketBeat
Avidity Partners Management LP's Strategic Acquisition in Immuni - GuruFocus.com
Richard Rudick Spends US$100k On Immunic Stock - Simply Wall St
Insider Buys Additional US$100k In Immunic Stock - Yahoo Finance
Janus Henderson Group PLC's Strategic Reduction in Immunic Inc H - GuruFocus.com
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - The Malaysian Reserve
RTW INVESTMENTS, LP Acquires Additional Shares in Immunic Inc - GuruFocus.com
Immunic announces publication of IMU-856 data - Yahoo Finance
Director Richard Rudick Acquires 87,300 Shares of Immunic Inc (I - GuruFocus.com
Immunic director Richard Rudick buys $100,368 in stock By Investing.com - Investing.com Australia
Immunic director Richard Rudick buys $100,368 in stock - Investing.com
Immunic announces publication of IMU-856 Phase 1 trial data in peer-reviewed journal - Proactive Investors USA
Immunic reports positive Phase 1 results for celiac disease therapy published in The Lancet - Proactive Investors USA
Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology - PR Newswire
Immunic, Inc. (NASDAQ:IMUX) Q3 2024 Earnings Call Transcript - Insider Monkey
Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges By GuruFocus - Investing.com Canada
Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic P - GuruFocus.com
Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges - Yahoo Finance
Immunic Reports Q3 Earnings and Provides Corporate Update - TipRanks
Immunic, Inc. Advances MS Trials Amid Financial Update - TipRanks
Immunic, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Immunic: Q3 Earnings Snapshot - Milford Mirror
Immunic Inc (IMUX) Quarterly 10-Q Report - Quartzy
Immunic Reports Third Quarter 2024 Financial Results and Provides Corporate Update - citybiz
Immunic highlights progress in multiple sclerosis programs, targets 2025 milestones - Proactive Investors USA
Immunic CEO details progress following productive third quarter - Proactive Investors UK
Immunic's Phase 3 MS Trial Advances Despite Wider Q3 Loss; $59.1M Cash Runway | IMUX Stock News - StockTitan
Immunic's Jessica Breu talks BIO-Europe & MS research advancements - Proactive Investors USA
Vanguard Group's Strategic Acquisition of Immunic Inc Shares - GuruFocus.com
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update - Quantisnow
Immunic (IMUX) Set to Announce Quarterly Earnings on Thursday - MarketBeat
EQS-News: Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Updateboerse.de - boerse.de
Immunic to Participate in Industry, Scientific and Investor Conferences in November - StockTitan
Brokerages Set Immunic, Inc. (NASDAQ:IMUX) PT at $11.20 - MarketBeat
Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 29.5% in October - MarketBeat
Reviewing Immunic (NASDAQ:IMUX) & Acasti Pharma (NASDAQ:ACST) - Defense World
We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate - Simply Wall St
Immunic Therapeutics CMO Dr. Andreas Muehler on Positive Interim Analysis for RMS Trials - Proactive Investors Australia
Immunic late-stage program for lead asset to proceed as planned - MSN
Data monitoring committee OKs continuation of phase 3 trial for vidofludimus calcium - Healio
Interim analysis allows Immunic to stick with phase III MS studies - BioWorld Online
Immunic stock slips after trial update (IMUX:NASDAQ) - Seeking Alpha
Immunic Phase 3 MS study advances following positive recommendation from independent committee - Proactive Investors Australia
Immunic Shares Up 12% on Positive MS Drug Analysis - MarketWatch
Immunic's phase 3 ENSURE trials for MS drug proceed as planned - Investing.com
Immunic, Inc. Announces Positive Outcome of Interim Analysis of Phase 3 Ensure Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis - Marketscreener.com
EQS-News: Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosisboerse.de - boerse.de
Immunic Stock Set to Rise with Consistent Buy Ratings from Analysts - Nasdaq
Finanzdaten der Immunic Inc-Aktie (IMUX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):